2 results
Suicide Deaths Before and During the COVID 19 Pandemic
- R. Rossom, R. Penfold, A. Owen-Smith, G. Simon, B. Ahmedani
-
- Journal:
- European Psychiatry / Volume 66 / Issue S1 / March 2023
- Published online by Cambridge University Press:
- 19 July 2023, p. S88
-
- Article
-
- You have access Access
- Open access
- Export citation
-
Introduction
With stressors that are often associated with suicide increasing during the coronavirus disease 2019 (COVID-19) pandemic, there has been concern that suicide mortality rates may also be increasing. Our objective was to determine whether suicide mortality rates increased during the COVID-19 pandemic.
With stressors that are often associated with suicideincreasing during the coronavirus disease 2019 (COVID-19) pandemic,there has been concern that suicide mortality rates may alsobe increasing.
ObjectivesOur objective was to determine whether suicidemortality rates increased during the COVID-19 pandemic.
MethodsWe conducted an interrupted time-series study using data from January 2019 through December 2020 from 2 large integrated health care systems. The population at risk included all patients or individuals enrolled in a health plan at HealthPartners in Minnesota or Henry Ford Health in Michigan. The primary outcome was change in suicide mortality rates, expressed as annualized crude rates of suicide death per 100,000 people in 10 months following the start of the pandemic in March 2020 compared with the 14 months prior. We conducted an interrupted time-series study using data fromJanuary 2019 through December 2020 from 2 large integrated health care systems. The population at risk included all patients or individuals enrolledin a health plan at HealthPartners in Minnesota or Henry Ford HealthSystem in Michigan. The primary outcome was change in suicide mortality rates, expressed as annualized crude rates of suicide death per 100,000 people in 10 months following the start of the pandemic in March2020 compared with the 14 months prior.
ResultsThere were 6,434,675 people at risk in the sample, with 55% women and a diverse sample across ages, race/ethnicity, and insurance type. From January 2019 through February 2020, there was a slow increase in the suicide mortality rate, with rates then decreasing by 0.45 per 100,000 people per month from March 2020 through December 2020 (SE= 0.19, P=0.03). There were 6,434,675 people at risk in the sample, with 55% women and a diverse sample across ages, race/ethnicity, and insurance type. From January 2019 through February 2020, there was a slow increase in the suicide mortality rate, with rates then decreasing by 0.45 per 100,000 people per month from March 2020 through December 2020 (SE= 0.19, P=0.03).
ConclusionsOverall suicide mortality rates did not increase with the pandemic, and in fact slightly declined from March to December 2020. Our findings should be confirmed across other settings and, when available, using final adjudicated state mortality data. Overall suicide mortality rates did not increase with the pandemic, and in fact slightly declined from March to December 2020. Our findings should be confirmed across other settings and,when available, using final adjudicated state mortality data.
Disclosure of InterestNone Declared
A third gene affecting GABA transaminase levels in Aspergillans nidulus
- Christopher R. Bailey, Herbert N. Arst, Jr, Hugh A. Penfold
-
- Journal:
- Genetical Research / Volume 36 / Issue 2 / October 1980
- Published online by Cambridge University Press:
- 14 April 2009, pp. 167-180
-
- Article
-
- You have access Access
- Export citation
-
Mutations in the gatB gene as well as mutations in the putative structural gene gatA and the positive acting regulatory gene intA can affect γ-amino-n-butyrate (GABA) transaminase (EC 2.6.1.19) levels in the ascomycete fungus Aspergillus nidulans. Partial or complete loss of function mutations in gatA, gatB and ssuA, which specifies succinic semialdehyde dehydrogenase, can lead to accumulation of ω-amino acids resulting in pseudo-constitutivity and elevated expression of (retained) activities under intA control. These regulatory effects underlie selective methods for gatB−, ssuA− and leaky gatA− mutations. However, all three gatB− alleles which have been selected lead only to partial loss of GABA transaminase activity as judged by both in vivo and in vitro criteria. It has not been established whether the leakiness of these three gatB− mutations is an allele-specific or a locus-specific effect and whether or not the GABA transaminase present in gatB− strains differs from the wild type enzyme. Thus the role of the gatB product remains to be elucidated. The gatB gene is not closely linked to any other gene involved in ω-amino metabolism or related pathways.